Promising strategy to fight the most deadly brain tumor in children

(Ann&Robert H. Lurie Children's Hospital of Chicago) A study published in Nature Communications found that an inhibitor of an enzyme called ACVR1 slows tumor growth and increases survival in an animal model of diffuse intrinsic pontine glioma (DIPG) -- the most deadly brain tumor in children.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

In conclusion, we performed the largest study so far focused on CSF miRNA profiling in patients with brain tumors, and we believe that this new class of biomarkers have a strong potential as a diagnostic and prognostic tool in these patients.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
o Monica Fedele Glial tumors are the leading cause of cancer-related death and morbidity in children. Their diagnosis, mainly based on clinical and histopathological factors, is particularly challenging because of their high molecular heterogeneity. Thus, tumors with identical histotypes could result in variable biological behaviors and prognoses. The PATZ1 gene has been recently shown to be expressed in adult gliomas, including glioblastomas, where it correlates with the proneural subtype and with a better prognosis. Here, we analyzed the expression of PATZ1 in pediatric gliomas, first at mRNA level in a public data...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Purpose of review The current review summarizes recent advances on three important issues in neurofibromatosis type 1 (NF1) management: the identification of specific NF1 gene mutations predicting the risk for developing neurological malignancies; the molecular features of NF1-associated tumors and their differences from sporadic neoplasms; genetic, epigenetic, or microenviromental factors leading benign tumors to a malignant transformation in NF1. Recent findings The association between the risk of developing optic pathway glioma and specific germiline NF1 mutations is still debated and further studies are needed wit...
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: BRAIN AND NERVOUS SYSTEM: Edited by Marc Sanson Source Type: research
Abstract Significant progress on circulating tumor cells (CTCs) has profound impact for noninvasive tumor profiling including early diagnosis, treatment monitoring, and metastasis recognition. Therefore, CTCs based liquid biopsy technology is taking a rapid growth in the field of precision oncology. The label-free approaches relied on microfluidic chip stand out from a crowd of methods that suffer from time consuming, extensive blood samples, lost target cells and labor-intensive operation. In this paper, a label-free separation microfluidic device was developed using multistage channel, which took full advantage ...
Source: Talanta - Category: Chemistry Authors: Tags: Talanta Source Type: research
The contribution of the complement system in the pathophysiology of brain cancers has been recently considered in light of its well-known involvement in carcinogenesis. Complement system represents an important component of the inflammatory response, which acts as a functional bridge between the innate and adaptive immune response. C1q, the first recognition subcomponent of the complement classical pathway, has recently been shown to be involved in a range of pathophysiological functions that are not dependent on complement activation. C1q is expressed in the microenvironment of various types of human tumors, including mel...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Abstract13N-Ammonia (13N-NH3) is widely used positron emission tomography/computed tomography (PET/CT) radiotracer for the measurement of myocardial blood perfusion; the possible role of13N-NH3 PET or PET/CT in oncological disease is not yet clear. Aim of this review is to evaluate the diagnostic performances of13N-NH3 PET in this field. A comprehensive computer literature search of the PubMed/MEDLINE, Scopus, and Embase databases was conducted including articles up to June 2019. Eighteen articles were finally included in the review. From the analyses of the selected studies, the following main findings could be drawn: (1)...
Source: Japanese Journal of Radiology - Category: Radiology Source Type: research
ConclusionsOur results indicate that DS-1001b, which is currently in a phase I clinical trial for treating glioma with IDH1 mutations (NCT03030066), is BBB-permeable and effective against the PDX model of IDH1 mutant glioma through inhibition of IDH1 mutant proteins.Clinical trial identificationNCT03030066.Legal entity responsible for the studyDaiichi Sankyo Co., Ltd.FundingDaiichi Sankyo Co., Ltd.DisclosureH. Matsunaga: Full / Part-time employment: Daiichi Sankyo Co., Ltd. Y. Machida: Research grant / Funding (institution): Daiichi Sankyo Co., Ltd. M. Nakagawa: Research grant / Funding (institution): Daiichi Sankyo Co., L...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundImmune therapies targeting the programmed cell death receptor (ligand) 1 (PD-1/PD-L1) axis have shown remarkable activity in a variety of solid tumors. While substantial responses were observed in asymptomatic patients with brain metastases (BM), their clinical activity in primary brain tumors remains limited. In a cohort of adult brain tumor patients, we aimed to analyze soluble PD-L1 (sPD-L1) levels in patient plasma as a systemic marker of tumor - immune system interactions.MethodsWe obtained EDTA plasma from 55 glioblastoma, 26 lower-grade (WHO grade II - III) glioma (LGG), 17 meningioma and 43 BM pat...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsIO seems to be ineffective in HmGB with somatic mut regardless the onset of diagnosis (newly/recurrent) or type of Hm phenotype. However, germline HmGB may have durable responses to IO. Further investigation is needed to determine the potential antitumor immune response in this population.Legal entity responsible for the studyThe authors.FundingThis work was supported in part by the Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, and the MD Anderson Cancer Center Support grant (P30 CA016672) MD Anderson Cancer Center.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Conclusions1. Glioblastoma, anaplastic glioma and neuroblastoma cell lines have a high sensitivity to Cabazitaxel in vitro. 2. Cell lines with MGMT methylation and MMR expression (A172 and LN 229) are the most sensitive. Of them, line A172 presents a p53 wild type, and therefore, a greater sensitivity to Cabazitaxel. 3. The expression of CD133 correlates inversely with the values of IC50 to Cabazitaxel, and may also be a predictor of response.Legal entity responsible for the studyUGR.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Brain | Brain Cancers | Brain Tumor | Cancer | Cancer & Oncology | Children | Glioma | Hospitals | Neurology | Study